Phosphagenics starts TPM-02/Insulin trial

By Elaine Rigoli

Tampa, Fla., July 24 - Phosphagenics Ltd. has started the phase 1 clinical trial of its transdermal insulin-delivery product, TPM-02/Insulin.

The company said the primary objective is to assess the safety and tolerability of this delivery platform in delivering insulin through the skin. Blood glucose and insulin levels will also be measured as secondary outcomes.

In the proposed study, 20 healthy male volunteers aged between 18 and 45 will be randomly assigned to receive either TPM-02/Insulin or a placebo gel, applied in a single dose directly to the skin.

Patients will then be monitored for 48 hours, the company said in a news release.

The trial is expected to be completed by the end of July, with a full analysis anticipated by September, the release said.

Phosphagenics is a biotechnology company based in Melbourne, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.